- Home
- SPRO vs NAMI Comparison
SPRO vs NAMI Comparison
Compare SPRO & NAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- NAMI
- Stock Information
- Founded
- SPRO 2013
- NAMI 2014
- Country
- SPRO United States
- NAMI China
- Employees
- SPRO N/A
- NAMI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- NAMI
- Sector
- SPRO Health Care
- NAMI
- Exchange
- SPRO Nasdaq
- NAMI NYSE
- Market Cap
- SPRO 162.1M
- NAMI 185.3M
- IPO Year
- SPRO 2017
- NAMI 2024
- Fundamental
- Price
- SPRO $2.18
- NAMI $0.87
- Analyst Decision
- SPRO Buy
- NAMI
- Analyst Count
- SPRO 4
- NAMI 0
- Target Price
- SPRO $5.00
- NAMI N/A
- AVG Volume (30 Days)
- SPRO 784.3K
- NAMI 30.4K
- Earning Date
- SPRO 08-12-2025
- NAMI 08-12-2025
- Dividend Yield
- SPRO N/A
- NAMI N/A
- EPS Growth
- SPRO N/A
- NAMI N/A
- EPS
- SPRO N/A
- NAMI 0.10
- Revenue
- SPRO $44,584,000.00
- NAMI $55,677,960.00
- Revenue This Year
- SPRO N/A
- NAMI N/A
- Revenue Next Year
- SPRO N/A
- NAMI N/A
- P/E Ratio
- SPRO N/A
- NAMI $9.48
- Revenue Growth
- SPRO N/A
- NAMI 7.00
- 52 Week Low
- SPRO $0.51
- NAMI $0.86
- 52 Week High
- SPRO $3.22
- NAMI $7.75
- Technical
- Relative Strength Index (RSI)
- SPRO 32.49
- NAMI N/A
- Support Level
- SPRO $2.30
- NAMI N/A
- Resistance Level
- SPRO $2.45
- NAMI N/A
- Average True Range (ATR)
- SPRO 0.11
- NAMI 0.00
- MACD
- SPRO -0.07
- NAMI 0.00
- Stochastic Oscillator
- SPRO 2.03
- NAMI 0.00
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The company generates revenue by selling its content to hardware manufacturers in China whereby are allowed to install the company's digital educational content on the manufacturers' devices for sale to end users.